Platelet Aggregation Inhibitor Drug Class List

Drugs in Drug Class: Platelet Aggregation Inhibitor

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Aurobindo Pharma Ltd	ACETAMINOPHEN, ASPIRIN AND CAFFEINE	acetaminophen; aspirin; caffeine	TABLET;ORAL	211695-001	Feb 2, 2022		OTC	No	No
Granules	ACETAMINOPHEN, ASPIRIN AND CAFFEINE	acetaminophen; aspirin; caffeine	TABLET;ORAL	214039-001	Feb 23, 2021		OTC	No	No
Medicure	AGGRASTAT	tirofiban hydrochloride	INJECTABLE;INJECTION	020912-001	May 14, 1998		DISCN	No	No
Medicure	AGGRASTAT	tirofiban hydrochloride	SOLUTION;INJECTION	020912-002	Aug 31, 2016		RX	Yes	Yes
Medicure	AGGRASTAT	tirofiban hydrochloride	SOLUTION;INTRAVENOUS	020913-002	May 17, 2002	AP	RX	Yes	No
Perrigo	ACETAMINOPHEN, ASPIRIN AND CAFFEINE	acetaminophen; aspirin; caffeine	TABLET;ORAL	075794-001	Nov 26, 2001		OTC	No	No

rket Dynamics and Patent Landscape for Platelet Aggregation Inhibitors
The platelet aggregation inhibitors market is experiencing robust growth driven by rising cardiovascular disease prevalence and technological advancements, while facing challenges from drug interactions and patent expirations. This analysis examines key market trends, competitive dynamics, and patent developments shaping this critical pharmaceutical sector.

Market Dynamics

Growth Drivers

• Epidemiological Factors:
  An aging global population and increasing lifestyle-related diseases (e.g., diabetes, obesity) are primary growth drivers. The market is projected to reach $4.27 billion by 2032 from $1.12 billion in 2021, growing at an 18.24% CAGR[7]. Alternate projections estimate $5.06 billion by 2032 with an 8.2% CAGR[5].
• Technological Innovation:
  Advances include novel agents like ticagrelor (rapid onset, reversible inhibition)[5] and precision medicine approaches using genetic testing to address clopidogrel resistance caused by CYP2C19 polymorphisms[12].

| Drug Class       | Key Features                                  | Market Position        |
|------------------|-----------------------------------------------|------------------------|
| Aspirin          | Affordable, widely available                 | >50% prescription share|
| Ticagrelor       | Faster action, reversible inhibition         | 12% annual growth[5]   |
| Cangrelor        | IV formulation for perioperative use         | Patent protected[2]    |

Competitive Landscape

• Key Players: ABC Pharmaceuticals, XYZ Corporation, and Boehringer Ingelheim dominate through R&D investments and strategic collaborations[1].
• Emerging Trends:
  • Dual antiplatelet therapy (DAPT) adoption, combining aspirin with P2Y12 inhibitors[12]
  • Biosimilars for monoclonal antibody therapies entering late-stage development[6]

---

Patent Landscape

Key Patent Developments

1. Therapeutic Methods:

   • US-8759316-B2: Covers cangrelor administration pre-surgery to maintain platelet inhibition[2]
   • EP0804418B1: Synthetic peptides targeting GP IIb/IIIa receptors[3]

2. Natural Product Derivatives:

   • US5756451: Snake venom-derived peptides inhibiting fibrinogen binding[8][9]
   • AU636159C: Recombinant production methods for venom-derived inhibitors[8]

3. Formulation Patents:

   • US5602155A: Non-peptide RGD analogs with 11-atom spacers[11]

Patent Expirations (2025 Impact)

Drug	Company	2024 Revenue	Threat Level
Clopidogrel	Generic manufacturers	$1.8bn	High
Ticagrelor	AstraZeneca	$1.2bn	Medium
Prasugrel	Daiichi Sankyo	$890m	Low

Generics account for 90% of U.S. prescriptions post-patent expiry, driving price reductions up to 50%[6]. Biosimilar competition for biologics like Eylea (aflibercept) will intensify post-2025[10].

---

Clinical and Regulatory Considerations

Safety Challenges

• Bleeding Risks: 12-15% of patients experience bleeding complications requiring therapy adjustment[12]
• Drug Interactions:
  • Rabeprazole reduces clopidogrel efficacy by 44%[4]
  • Simvastatin decreases antiplatelet activity by 31%[4]

"Personalized dosing protocols using pharmacogenomics are becoming essential to balance thrombotic protection and bleeding risk." - Clinical Cardiology Review[4]

Pandemic Impacts

COVID-19 caused 18% supply chain disruptions[1], but accelerated telehealth adoption improved post-discharge monitoring of antiplatelet regimens.

---

Future Outlook

1. Pipeline Innovations: 23 novel agents in Phase III trials targeting PAR-1 and thromboxane receptors
2. Market Opportunities:
   • APAC region growth at 22% CAGR due to healthcare infrastructure improvements[7]
   • Point-of-care testing integration with automated platelet analyzers[7]

This evolving landscape demands continuous R&D investment and agile IP strategies to maintain competitiveness amidst genericization and precision medicine advancements.

References

1. https://markwideresearch.com/platelet-aggregation-inhibitors-market/
2. https://pubchem.ncbi.nlm.nih.gov/patent/US8759316
3. https://patents.google.com/patent/EP0804418B1/en
4. https://clinmedjournals.org/articles/ijcc/international-journal-of-clinical-cardiology-ijcc-7-188.php?jid=ijcc
5. https://www.datamintelligence.com/research-report/antiplatelet-drugs-market
6. https://pmarketresearch.com/hc/antifibrinolytic-drugs-market/antiplatelet-drugs-market
7. https://www.maximizemarketresearch.com/market-report/platelet-aggregation-inhibitors-market/72806/
8. https://patents.google.com/patent/AU636159C/en
9. https://www.drugpatentwatch.com/p/patent/5756451
10. https://biopharmaapac.com/analysis/60/5727/25-high-value-drugs-losing-patent-protection-in-2025-what-it-means-for-healthcare.html
11. https://patents.google.com/patent/US5602155A/en
12. https://www.cognitivemarketresearch.com/antiplatelet-drugs-market-report
13. https://japsonline.com/admin/php/uploads/3655_pdf.pdf